Laurus Labs
BSE 540222
6 stories, newest first.
- ESG rating of 82.6 with CareEdge-ESG 1+ symbol assigned by CARE ESG Ratings
- Laurus Labs invests INR 107.8 crore in KRKA Pharma rights issue; 49% holding unchanged
- Laurus Labs Q2 & H1 FY27 earnings conference call on October 29, 2026, hosted by DAM Capital Advisors
- Board meeting on October 29, 2026 to consider September quarter results and interim dividend proposal
- Laurus Labs invests INR 12,09,60,500 in Kurnool Renewables rights issue; 26% stake unchanged
- Laurus Labs stock has quadrupled in market cap over two years driven by CDMO business growth; analyst flags expensive valuation despite strong earnings outlook
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.